When was Visus Therapeutics founded?

Visus Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Visus Therapeutics located?

Visus Therapeutics is headquartered in Seattle, United States. It is registered at Rīga, Plēksnes iela 3 - 32.

How many employees does Visus Therapeutics have?

As of May 31, 2026, the latest employee count at Visus Therapeutics is 131.

Is Visus Therapeutics a funded company?

Visus Therapeutics is a funded company, having raised a total of $56M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 09, 2021.

When was the latest funding round of Visus Therapeutics?

Visus Therapeutics' latest funding was a $***** Series A round on Aug 17, 2021, with participation from 3 investors.

Where does Visus Therapeutics rank among its competitors?

Visus Therapeutics ranks 34th amongst 118 active competitors, of which 44 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Kala Pharmaceuticals, which secured $1.75M in Mar, 2026.

Who are the top competitors of Visus Therapeutics?

Visus Therapeutics' top competitors include 4D Molecular Therapeutics, Regenxbio and CureVac. Among them, Kala Pharmaceuticals secured the most recent funding round in March, 2026.

Visus Therapeutics - 2026 Company Profile, Funding & Competitors

Visus Therapeutics is a series A company based in Seattle (United States), founded in 2019. It operates as a Developer of therapeutic solutions for vision care. Visus Therapeutics has raised $56M in funding from investors like Life Sciences Partners, Sage and Johnson & Johnson Innovation. The company has 118 active competitors, including 44 funded and 23 that have exited. Its top competitors include companies like 4D Molecular Therapeutics, Regenxbio and CureVac.

Company Details

Developer of therapeutic solutions for vision care. The company has developed BRIMOCHOL VTL-001 small molecules to correct the loss of near vision associated with presbyopia. Another product VTI-003 peptide helps in treating ocular surface diseases.

Website: visustx.com
Social
Phone Number: +1 **********
Registered Address: Rīga, Plēksnes iela 3 - 32

Key Metrics

Founded Year

2019

Location

Seattle, United States

Stage

Series A

Total Funding

$56M in 2 rounds

Latest Funding Round

Series A, Aug 17, 2021, $*****

Investors

Life Sciences Partners & 7 more

Ranked

34^th among 118 active competitors

Employee Count

131 as on May 31, 2026

Similar Companies

4D Molecular Therapeutics & 122 more

View Visus Therapeutics' full profile

Visus Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VisuS CIN: 40103598890 , Latvia, Active	Oct 22, 2012	€0 - €1M (As on Dec 31, 2024)	1 (As on Dec 31, 2022)	-
Visus Therapeutics, Inc. CIN: 84-3379554 , United States, Active	Oct 08, 2019	-	35 (As on Dec 31, 2021)	-

Visus Therapeutics has raised a total funding of $56M over 2 rounds. Its first funding round was on Mar 09, 2021. Its latest funding round was a Series A round on Aug 17, 2021 for $*****. 3 investors participated in its latest round. Visus Therapeutics has 8 institutional investors.

Here is the list of recent funding rounds of Visus Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 17, 2021	6786278	Series A	8268475	6933807	5317512	4016733
Mar 09, 2021	2849274	Series A	9489365	7390939	RTW Investments & 1 more	Wille Finance

Access funding benchmarks and valuations. Sign up today!

View details of Visus Therapeutics's funding rounds and investors

Visus Therapeutics' employee count trend

Visus Therapeutics has 131 employees as of May 26. Here is Visus Therapeutics's employee count trend over the years:

Employee count trend for Visus Therapeutics

Uncover Visus Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Visus Therapeutics include 4D Molecular Therapeutics, Regenxbio and CureVac. Here is the list of Top 10 competitors of Visus Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Viking Global Investors, BVF Partners & 18 others	68/100
2nd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
3rd	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
4th	Kala Pharmaceuticals 2009, Waltham (United States), Public	Developer of ophthalmic treatments based on its mucosal penetrating product platform	$115M	Polaris Partners, Lux Capital & 17 others	66/100
5th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Lincoln Park Capital & 8 others	64/100
6th	AAVantgarde Bio 2021, Milano (Italy), Series B	Developer of gene therapies using Adeno-Associated Viral vectors	$206M	Atlas Venture, Forbion & 11 others	63/100
7th	Aviceda Therapeutics 2018, Cambridge (United States), Series C	Developer of biotherapeutics for glycol-immune diseases	$255M	Omega Funds, Marshall Wace & 10 others	62/100
8th	Outlook Therapeutics 2011, Cranbury (United States), Public	Developer of antibodies for ophthalmic disorders	$51.8M	Perceptive Advisors, Avoro Capital & 12 others	61/100
9th	Complement Therapeutics 2020, London (United Kingdom), Series A	Developer of gene therapies to treat retinal diseases	$84.8M	Forbion, Gimv & 7 others	61/100
10th	Opus Genetics 2021, Durham (United States), Public	Developer of gene therapies to treat retinal degenerative diseases	$23.5M	RD Fund, Bios Partners & 2 others	59/100
34th	Visus Therapeutics 2019, Seattle (United States), Series A	Developer of therapeutic solutions for vision care	$56M	RTW Investments, Gershon Capital & 6 others	44/100